Cited by 3

An Overview of Biotechnological Drug's Various Techniques of Downstream Process, Guideline's and Different Chromatographic Analysis

Demir, Filiz, Albarri, Raneen, Unal, Durisehvar Ozer·2024·Current Pharmaceutical Analysis

Abstract

Biotechnology, a field discovered in 1919, unites biology and engineering to harness living organisms for medical purposes. Fueled by using DNA's discovery in the 1950s, biotechnology has converted through genetic engineering, yielding impactful merchandise regulated by means of entities like the FDA. The manufacturing involves upstream and downstream processing including the various techniques involved in the downstream processing of biotechnological drugs, along with relevant guidelines and chromatographic analysis methods. The biotechnological industry, which integrates biological science with engineering, has significantly advanced since the discovery of DNA's structure, leading to the development of biopharmaceuticals. These drugs, including monoclonal antibodies, recombinant proteins, and gene therapies, are produced using living organisms and hold the potential for treating complex diseases. The downstream process, a crucial phase in biopharmaceutical production, involves the purification and formulation of drug products to meet stringent regulatory standards. Traditional techniques such as centrifugation, filtration, and chromatography are employed to extract and purify biopharmaceuticals. Chromatographic techniques, including ion exchange, affinity, and size exclusion chromatography, play a pivotal role in achieving the desired purity levels. However, these methods are often time-- consuming and expensive, necessitating continuous advancements in the field. The paper highlights the importance of regulatory guidelines, including cGMP, in ensuring the quality and safety of biopharmaceuticals. It also discusses the significant role of organizations such as the FDA and EMA in regulating biotechnological drug production. The evolution of downstream processing techniques and the development of novel methods promise greater efficiency, scalability, and cost-effectiveness in biopharmaceutical production. Understanding these advancements is essential for continued growth and innovation in the industry, ultimately contributing to improved patient care and pharmaceutical innovation.

Integrity signals

Registry

Crossref · 10.2174/0115734129317408240903150800

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Downstream processing accounts for 80% of production expenses, largely driven by the high cost of Protein A resin and virus filtration.

    “Purification often exceeds the cost of upstream manufacturing, with downstream processing accounting for 80% of production expenses, largely driven by the high cost of Protein A resin and virus filtration [14, 23].”

Cited by

Sorted by citations

Authors
Demir, F., Albarri, R., & Unal, D. O.
Affiliations
  • Faculty of Pharmacy, Department of Analytical Chemistry, Institute of Health Science, Istanbul University, 34126, Beyazit, Istanbul, Turkey
  • Faculty of Pharmacy, Department of Analytical Chemistry, Istanbul University, 34116, Beyazit, Istanbul, Turkey
Venue
Current Pharmaceutical Analysis
Publisher
Elsevier BV
Published
2024-12
Volume
20
Issue
8
Pages
729-742
ISSN
1573-4129
Cited by
3
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review